Cargando…
IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392968/ https://www.ncbi.nlm.nih.gov/pubmed/35694767 http://dx.doi.org/10.17305/bjbms.2022.7279 |
_version_ | 1784771169109409792 |
---|---|
author | Xu, Yipeng Pachnikova, Gabriela Wang, He Wu, Yaoyao Przybilla, Dorothea Schäfer, Reinhold Chen, Zihao Zhu, Shaoxing Keilholz, Ulrich |
author_facet | Xu, Yipeng Pachnikova, Gabriela Wang, He Wu, Yaoyao Przybilla, Dorothea Schäfer, Reinhold Chen, Zihao Zhu, Shaoxing Keilholz, Ulrich |
author_sort | Xu, Yipeng |
collection | PubMed |
description | Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC(50) ) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids’ susceptibility to treatment was more complicated; the fitness of IC(50) curves of 2D and 3D tumor cell preclinical models differs significantly. IC(50) curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically. |
format | Online Article Text |
id | pubmed-9392968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-93929682022-08-22 IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation Xu, Yipeng Pachnikova, Gabriela Wang, He Wu, Yaoyao Przybilla, Dorothea Schäfer, Reinhold Chen, Zihao Zhu, Shaoxing Keilholz, Ulrich Bosn J Basic Med Sci Research Article Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC(50) ) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids’ susceptibility to treatment was more complicated; the fitness of IC(50) curves of 2D and 3D tumor cell preclinical models differs significantly. IC(50) curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022-08 2022-06-09 /pmc/articles/PMC9392968/ /pubmed/35694767 http://dx.doi.org/10.17305/bjbms.2022.7279 Text en Copyright: © The Author(s) (2022) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Research Article Xu, Yipeng Pachnikova, Gabriela Wang, He Wu, Yaoyao Przybilla, Dorothea Schäfer, Reinhold Chen, Zihao Zhu, Shaoxing Keilholz, Ulrich IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title | IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title_full | IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title_fullStr | IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title_full_unstemmed | IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title_short | IC(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
title_sort | ic(50): an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392968/ https://www.ncbi.nlm.nih.gov/pubmed/35694767 http://dx.doi.org/10.17305/bjbms.2022.7279 |
work_keys_str_mv | AT xuyipeng ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT pachnikovagabriela ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT wanghe ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT wuyaoyao ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT przybilladorothea ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT schaferreinhold ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT chenzihao ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT zhushaoxing ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation AT keilholzulrich ic50anunsuitablemeasureforlargesizedprostatecancerspheroidsindrugsensitivityevaluation |